Poly(ADP-ribose) Polymerases
"Poly(ADP-ribose) Polymerases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE.
| Descriptor ID |
D011065
|
| MeSH Number(s) |
D08.811.913.400.725.115.690
|
| Concept/Terms |
Poly(ADP-ribose) Polymerases- Poly(ADP-ribose) Polymerases
- ADP-Ribosyltransferase (Polymerizing)
- Poly(ADP-ribose) Polymerase
- Poly ADP Ribose Polymerase
- Poly ADP Ribose Transferase
- Poly(ADP-Ribose) Transferase
- PARP Polymerase
- Polymerase, PARP
- Poly(ADPribose) Polymerase
- Poly ADP-Ribose Synthase
- Poly ADP Ribose Synthase
- Synthase, Poly ADP-Ribose
- Poly(ADPR) Polymerase
- Poly(ADP-Ribose) Synthase
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerases".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerases".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerases" by people in this website by year, and whether "Poly(ADP-ribose) Polymerases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2009 | 3 | 1 | 4 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 3 | 1 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 3 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerases" by people in Profiles.
-
PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice. Cell Rep. 2025 Aug 26; 44(8):116130.
-
Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair. Semin Cancer Biol. 2024 01; 98:11-18.
-
Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production. J Clin Invest. 2023 06 15; 133(12).
-
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecol Oncol. 2023 03; 170:172-178.
-
Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges. Cancer Treat Res. 2023; 186:143-170.
-
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. JCO Precis Oncol. 2022 06; 6:e2100531.
-
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecol Oncol. 2022 07; 166(1):117-125.
-
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
-
TiPARP forms nuclear condensates to degrade HIF-1a and suppress tumorigenesis. Proc Natl Acad Sci U S A. 2020 06 16; 117(24):13447-13456.
-
PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther. 2020 09; 213:107588.